SZSE •
Healthcare •
Biotechnology •
Quote as of 06/18/2026 15:04
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeSZSE
Market Capitalization11,291 mln
Float532 mln
EPS
0.37
Marginal
P / E
29.22
Elevated
Piotroski F-Score
2
/ 9
Weak
Beneish M-Score
-1.35
Manipulation likely
Relative Strength
3
/ 100
Severely lagging
Debt / Equity
0.10
Very low leverage
Business Description
Founded in 1993 and based in Taiyuan, China, Pacific Shuanglin Bio-pharmacy develops, manufactures, and sells a range of blood-derived medical products for both domestic and international markets. Its portfolio includes treatments such as human serum albumin, various immunoglobulins, clotting factors, and fibrinogen, which are used to treat or prevent serious conditions including rabies, hepatitis B, and tetanus. The company also provides consulting, trading, and technical services in the pharmaceutical and biotechnology sectors.
